Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 7 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

57%

4 trials in Phase 3/4

Results Transparency

0 of 5 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 3

3(42.9%)

N/A

2(28.6%)

Phase 1

1(14.3%)

Phase 4

1(14.3%)

7Total

Phase 3(3)

N/A(2)

Phase 1(1)

Phase 4(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials

NCT05512858Not ApplicableCompleted

Sensory Room at an Acute Psychiatric Unit

Role: collaborator

NCT02480400Not ApplicableCompleted

The Effect of Patient and Investigator Expectation on the Efficacy of Escitalopram in the Treatment Depression

Role: lead

NCT01119638Phase 4Completed

Escitalopram Treatment for BPSD in Alzheimer's Disease in Comparison to Risperidone

Role: lead

NCT00863291Phase 3Unknown

A Double-Blind Study of Buprenorphine Treatment of Acute Suicidality

Role: lead

NCT00733057Phase 3Completed

Minocycline for the Treatment of Early-Phase Schizophrenia

Role: collaborator

NCT00409201Phase 1Unknown

Reboxetine Adjuvant Therapy for the Treatment of Schizophrenia

Role: lead

NCT00305500Phase 3Completed

Tolerability and Efficacy of High Dose Escitalopram for the Treatment of Obsessive-Compulsive Disorder (OCD)

Role: lead

All 7 trials loaded